CVS Health spent years arguing that insurance, pharmacy benefits, clinics and retail stores were worth more together. It is now preparing to test the opposite idea.
On November 4, 2026, the company announced plans to separate into two publicly traded businesses. One will keep the CVS Health name and own Aetna, CVS Caremark, CVS Specialty, Oak Street Health and Signify Health. The other, CVS Pharmacy, will operate roughly 9,000 pharmacies, the mail-order business, MinuteClinic and the Health100 consumer platform.
The separation is expected to be completed in the first half of 2028, with existing CVS shareholders expected to receive shares in both companies.
The timing matters. CVS is not splitting up during a financial crisis. The announcement arrived alongside better-than-expected third-quarter results, improving insurance margins and another increase to full-year guidance. The question for CVS stock isn’t whether the company can survive. It’s whether two focused businesses will be worth more than the healthcare conglomerate investors own today.
CVS Is Unwinding Its Integrated Healthcare Strategy
CVS built its current structure through years of expensive acquisitions. The company bought pharmacy benefit manager Caremark, acquired Aetna for approximately $69 billion and later added Oak Street Health and Signify Health.
The original strategy was easy to understand. Aetna could direct members into CVS pharmacies and clinics, Caremark could manage their prescription benefits, and the company could control more of the healthcare journey. In theory, this would lower costs while creating additional revenue across the group.
In practice, the structure became difficult to value and increasingly difficult to defend. Aetna struggled with rising medical costs, the retail pharmacy business faced reimbursement pressure, and regulators questioned whether companies should be allowed to control both pharmacy benefit decisions and the pharmacies filling prescriptions.
The proposed split does not completely abandon integration. Aetna, Caremark, specialty pharmacy and care-delivery assets will remain together. What it does remove is the most visible source of conflict: ownership of a major PBM and one of America’s largest retail pharmacy chains inside the same public company.
A Strong Quarter Gave CVS Room to Make the Move
CVS reported third-quarter revenue of $108.4 billion, up 5.4% from the previous year. Adjusted earnings reached $2.09 per share, compared with $1.60 a year earlier.
Management raised its 2026 adjusted earnings forecast to at least $8.20 per share, above the previous range of $7.90 to $8.10. Expected operating cash flow was lifted even more sharply, from at least $11.5 billion to at least $15.5 billion.
The most important improvement came from Aetna. CVS’s Health Care Benefits division generated $912 million in adjusted operating income, up from $314 million in the same quarter last year. Its medical benefit ratio—the share of insurance premiums spent on medical care—improved from 92.8% to 91.3%.
A 91.3% ratio remains high, but the direction matters. CVS has been withdrawing from unprofitable markets, redesigning benefits and repricing insurance products. Those measures are beginning to repair margins.
The retail pharmacy business also delivered a better result than its revenue figure initially suggests. Revenue declined 2%, partly because of reimbursement pressure and lower prices for certain drugs, but adjusted operating income increased 10.6%. Prescription volume rose 1.9%, helped by assets acquired from Rite Aid.
These numbers support management’s argument that CVS is separating from a position of improving financial strength rather than desperation.
The Breakup Could Make CVS Easier to Value
CVS currently combines businesses with very different economics. Aetna carries insurance risk and is sensitive to medical utilization. Caremark processes pharmacy claims and earns service fees. Oak Street and Signify depend on care-delivery economics. CVS Pharmacy operates physical locations and must manage prescription reimbursement, retail demand and labor costs.
Placing all of those operations inside one stock makes it difficult to decide which part of the company is creating value and which part deserves a discount.
After the separation, the healthcare solutions company will offer direct exposure to insurance, pharmacy benefits and value-based care. Management estimates that these operations will generate approximately $320 billion in 2026 revenue.
CVS Pharmacy is expected to have approximately $145 billion in annual revenue, 140 million consumer touchpoints and around 9,000 locations. Its appeal will rest on prescription volume, cash generation, consumer health services and its ability to stabilize reimbursement economics.
This clearer structure could attract different investors. Some may prefer the growth and margin-recovery potential of Aetna and Caremark. Others may value the steadier cash flow and dividend profile of the pharmacy business.
That is the basic breakup thesis. The market may assign a higher combined valuation to two understandable companies than it currently gives to one complicated group.
The $57 Billion Question
CVS had approximately $57.2 billion of long-term debt at the end of September. The company has not yet explained how that debt will be divided between the two businesses.
This is not a minor detail. Debt allocation will influence interest expense, credit ratings, dividend capacity and the valuation multiple applied to each company.
The healthcare solutions company may receive more debt because it will retain many of the assets acquired during CVS’s expansion. It may also have stronger long-term growth prospects. CVS Pharmacy could generate reliable cash, but loading it with too much debt would limit investment in stores, technology and shareholder returns.
Management expects both companies to maintain investment-grade ratings and pay attractive dividends. Those commitments sound reassuring, but investors still need the numbers. Until CVS publishes the proposed balance sheets, it is impossible to determine whether the split creates value or merely moves liabilities between two tickers.
Separation costs are another unknown. Breaking apart technology systems, contracts, employees and shared services can be expensive. The transaction will also take more than a year, leaving the company exposed to changing regulation and business conditions before completion.
Aetna’s Recovery Is Real, but Not Complete
The improvement in Aetna’s earnings gives CVS stock a stronger foundation, but the insurance business is not free of risk.
Around 69% of Aetna’s Medicare Advantage members are enrolled in plans rated four stars or higher for 2027. That remains competitive, but it is below the previous year. Lower ratings can reduce the quality bonuses insurers receive from the federal government.
Analysts at TD Cowen estimated that the rating changes could create an unmitigated earnings headwind of roughly $720 million in 2028. CVS may offset some of the impact by changing benefits, pricing and geographic coverage, but aggressive adjustments could cost the company members.
Medical membership has already declined from 26.7 million to 26.1 million over the past year. The next stage of the turnaround must therefore show that Aetna can protect margins without shrinking its customer base too far.
Medical costs remain another variable. CVS raised guidance while maintaining a cautious view on elevated cost trends. A new increase in hospital use, prescription spending or senior-care costs could slow the recovery even if management continues to execute well.
Regulation May Have Helped Shape the Decision
CVS Caremark is one of the largest pharmacy benefit managers in the United States. PBMs negotiate drug prices and determine how prescriptions are reimbursed, giving them an important but controversial position between insurers, pharmaceutical companies and pharmacies.
Lawmakers and regulators have increased scrutiny of rebate practices, pricing transparency and the relationship between PBMs and affiliated pharmacies. Some states have considered or passed restrictions targeting companies that operate both businesses.
Separating CVS Pharmacy will not remove every regulatory problem. Caremark will remain a major PBM, and CVS Health will still own specialty pharmacy operations. The split could, however, make the structure easier to defend by reducing the direct connection between Caremark and thousands of CVS retail locations.
The timing also allows each company to respond independently to policy changes. The healthcare solutions business can focus on insurance and PBM rules, while CVS Pharmacy can concentrate on reimbursement, retail operations and consumer care.
The Breakup Changes the CVS Stock Thesis
CVS is no longer simply a turnaround story. It is now a sum-of-the-parts investment with an incomplete set of numbers.
The earnings recovery is credible. Aetna’s margins improved, retail pharmacy profit increased and operating cash flow exceeded earlier expectations. Those results give management financial room to complete a complex separation.
The bull case is that two focused companies receive higher valuations, maintain their dividends and allocate capital more effectively. The bear case is that separation costs, Medicare pressure and poorly distributed debt consume much of the expected value.
For now, the breakup makes CVS stock more interesting, but not necessarily easier to judge. The next major rerating is unlikely to come from another strategic presentation. It will come when investors can see the actual earnings, debt and cash flow assigned to each new company.
Readers can follow global financial and digital-asset markets through the Tapbit official website. Existing users can log in to Tapbit, while new users can register for a Tapbit account.
Frequently Asked Questions
Why is CVS Health splitting into two companies?
CVS says the separation will give each business a clearer strategy, independent capital structure and greater flexibility. The move may also reduce some of the regulatory and valuation complications created by owning insurance, PBM and retail pharmacy operations inside one company.
What will the two CVS companies own?
CVS Health will retain Aetna, CVS Caremark, CVS Specialty, Oak Street Health and Signify Health. CVS Pharmacy will own the retail stores, mail-order pharmacy, MinuteClinic and Health100 platform.
When will the CVS breakup happen?
The company expects to complete the separation during the first half of 2028. The transaction remains subject to final board approval, regulatory filings and other customary conditions.
